Nyxoah stock holds Buy rating at Stifel following DREAM publication

Investing.com - Stifel maintained its Buy rating and $12.00 price target on Nyxoah SA (NASDAQ:NYXH), representing a 58% upside from the current price of $7.58, following the publication of the DREAM study in the Journal of Clinical Sleep Medicine. According to InvestingPro data, analyst consensus remains bullish with targets ranging from $12.49 to $14.57.The peer-reviewed article, published late last week, presents findings from the previously disclosed top-line data for Nyxoah’s Genio device, which treats obstructive sleep apnea.Stifel views the publication as a positive development for Nyxoah , noting that management has indicated the paper will help secure reimbursement for the device ahead of what Stifel believes will be imminent FDA approval.The investment firm expects a single-site paper from Germany with approximately 30 implants to be released in the fourth quarter of 2025, potentially supporting Nyxoah’s commercial efforts in late 2025 and 2026.Stifel projects modest U.S. revenue of €1.2 million in the second half of 2025 for Nyxoah, with momentum building into 2026, and notes that in recent diligence, 63% of ENT physicians indicated they would seek training within six months of Genio’s approval and launch.In other recent news, Nyxoah SA reported its first-quarter earnings for 2025, revealing revenues of $1.1 million. This result did not meet Cantor Fitzgerald’s projection of $2.4 million and was also below the FactSet consensus estimate of $1.6 million. The company experienced a year-over-year revenue decline of approximately 15%, largely due to its performance in Germany, where it generates nearly all of its revenue. Additionally, Cantor Fitzgerald maintained an Overweight rating on Nyxoah, with a price target of $14.00, following the earnings announcement. These developments reflect the company’s ongoing challenges in its primary market.This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.